Nanexa: Valuation update after the rights issue - ABG
SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22 & Novo Nordisk collab.) New valuation range: SEK 1-6/share (SEK 2-5 prev.)
ANNONS
SEK 75m from rights issue
Last week, Nanexa announced the outcome of the rights issue. Approximately 34.7% of the offered shares were subscribed to, either with or without subscription rights, while guarantee commitments accounting for 27.1% of the shares were utilised, resulting in gross proceeds of SEK 75m (~62% of the offered volume of SEK 121m). This outcome did not surprise us, given that the share had been trading at around SEK 1 since the rights issue was announced. The dilution impact of the share issue equals approximately 55.3% of the total number of shares.
